Cancer treatment guidelines are constantly evolving.
In 2022 alone, the National Comprehensive Cancer Network® (NCCN) issued:3
205+
+19
And oncologists need to be able to make informed decisions.
As efficiently as possible
For every patient
Every day
80%
EVICORE HAS PIONEERED THE SOLUTION:
The Oncology Value-based Pathways program
An enhancement to our existing clinical decision support solution that leverages a patented methodology to support highest quality, lowest cost treatment decisions amidst rapidly changing evidence.
The program currently spans 51 value-based pathways, focusing on a select subset of cancers where value opportunities exist.
AND HERE’S THE IMPACT:
WANT MORE DETAILS?
Read the full research report recently published in the Journal of Clinical Pathways by a team led by Dr. Stephen Hamilton, EviCore’s Associate Chief Medical Officer for Oncology Programs.
The oncology value-based pathways program improves physician selection of value-based treatment regimens, resulting in significant cost savings.
are overwhelmed by the amount of information to keep up with.4
across
updates
new oncology drugs and biosimilars3
cancer guidelines
60
Value-based = best possible cancer care without unnecessary spending
How do we ensure oncology patients are prescribed the highest-quality, most affordable treatment regimen available?
expected increase in cancer treatment spending between 2022 and 20272
~91%
Americans living with a history of cancer1
~18M
IT’S A COMPLEX QUESTION, CONSIDERING THE CHALLENGES.
Regimen 2
Regimen 3
Regimen 4
Preferred
Preferred
Preferred
Other recommended
***
***
**
*
++
++
+
+
$
$$$$
$$
Value-based pathways used to determine kidney cancer treatment
The requesting physician makes the final decision on which NCCN regimen best meets the needs of their patient.
Then, the results are shared with the requesting physician.
Off pathway
On pathway
EviCore shares the evaluation findings with the requesting physician, identifying the highest quality NCCN treatment regimen that offers the best value.
Estimate plan spending for entire regimen
Cost
Side effects and toxicity
Safety
Clinical outcomes including survival and recurrence rates
Efficacy
EviCore evaluates NCCN-recommended treatment regimens based on three key priorities:
HERE’S HOW IT WORKS:
$$
YES
NO
NO
NO
NCCN Status
Efficacy
Safety
Cost
Value-based Determination
$170,000
Projected savings on drug costs by switching to value-based regimen
value-based
Regimen 1
Preferred
***
++
$
YES
Regimen 1
1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022-2024. Atlanta: American Cancer Society; 2022.
Go to Report
Physician Selection of Value-Based Treatment Regimens
2. IQVIA. Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer. IQVIA Institute for Human Data Science; 2023.
4. Physician Learning Preferences. Doximity. October 2022. Accessed November 16, 2022.
3. Derived from NCCN updates shared with EviCore in 2022.
5.
Example
Decision
Communication
Evaluation
Communication
Evaluation
Decision
Example
of providers
or
$24M
reduced drug spend5
5
Journal of Clinical Pathways. Oncology Pathways Drive Adoption of High-Quality Treatment Regimens and Deliver Drug Cost Savings. Clinical Pathways Learning Network; 2023.
PRE VP PROGRAM
POST VP PROGRAM
69%
70%
71%
72%
73%
74%
75%
76%
77%
78%
79%
71.9%
77.1%
Cancer is prevalent and growing.
How do we ensure oncology patients are prescribed the highest-quality, most affordable treatment regimen available?
+
+
+
+
+
+
